Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

FightMND

  • Home
  •  
  • FightMND



  • Most Read
  • Latest Comments
  • PharmAust invited by FightMND to submit a funding request for up to $1.8m
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • PharmAust invited by FightMND to submit a funding request for up to $1.8m
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • PharmAust invited by FightMND to submit a funding request for up to $1.8m
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • PharmAust invited by FightMND to submit a funding request for up to $1.8m
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • PharmAust invited by FightMND to submit a funding request for up to $1.8m
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • PharmAust invited by FightMND to submit a funding request for up to $1.8m
    PharmAust invited by FightMND to submit a funding request for up to $1.8m
    • News

  • Drug that stops growth of cancerous cells shows positive results
    Drug that stops growth of cancerous cells shows positive results
    • News

  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • News

  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma
    A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma
    • News

  • The funs of chemistry: How this pharma company is tapping into lucrative waste management
    The funs of chemistry: How this pharma company is tapping into lucrative waste management
    • News

  • PharmAust invited by FightMND to submit a funding request for up to $1.8m
    • News

    PharmAust invited by FightMND to submit a funding request for up to $1.8m

    Biotech company PharmAust (ASX: PAA) has been invited by not-for-profit organisation FightMND to submit a comprehensive grant application which could grant up to $1.8 million to fund Phase 2 and 3 clinical trials in an effort to find a treatment for Motor Neurone Disease (MND) Earlier this month, PharmAust submitted a Letter of Intent to

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.